SLC5A2 and diabetic kidney disease: Recent advances for DN include sodium-glucose transport protein 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin; Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trials), finerenone (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial), and glucagon-like peptide-1 (GLP-1) receptor agonists, all improving renal and cardiovascular outcomes [121].